Product Details
| Product Name:
Elimusertib |
CAS No.:
1876467-74-1 |
| Purity:
99.75% |
Supply Ability:
10g |
| Release date:
2024/11/19 |
Product Introduction
Bioactivity
| Name | Elimusertib |
| Description | Elimusertib (BAY-1895344) is a potent, highly selective, and orally available ATR inhibitor with an IC50 of 7 nM, demonstrating significant anti-tumor efficacy as a monotherapy and strong combination potential with targeted alpha therapy Radium-223 dichloride. |
| In vivo | The novel selective ATR kinase inhibitor Elimusertib on tumor cell growth and viability.Potent antiproliferative activity was demonstrated in a broad spectrum of human tumor cell lines.Elimusertib exhibited strong monotherapy efficacy in cancer xenograft models that carry DNA damage repair deficiencies.The combination of Elimusertib with DNA damage-inducing chemotherapy or external beam radiotherapy (EBRT) showed synergistic antitumor activity.Combination treatment with Elimusertib and DDR inhibitors achieved strong synergistic antiproliferative activity in vitro, and combined inhibition of ATR and PARP signaling using olaparib demonstrated synergistic antitumor activity in vivo Furthermore, the combination of Elimusertib with the novel, nonsteroidal androgen receptor antagonist darolutamide resulted in significantly improved antitumor efficacy compared with respective single-agent treatments in hormone-dependent prostate cancer,and addition of EBRT resulted in even further enhanced antitumor efficacy[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 11 mg/mL (29.3 mM)
|
| Keywords | response | damage | ATM/ATR | stress | Inhibitor | tumors | DNA | instability | lymphomas | inhibit | solid | ATM and RAD3 related | Ataxia telangiectasia mutated | replication | genomic | BAY1895344 | repair | Elimusertib | BAY 1895344 |
| Inhibitors Related | CP-466722 | Ro 90-7501 | AZ31 | Dactolisib | Berzosertib | GJ103 sodium salt | KU60019 | Ceralasertib | (Z)-Mirin | NU6027 | Schisandrin B | AZ32 |
| Related Compound Libraries | Highly Selective Inhibitor Library | Bioactive Compound Library | Kinase Inhibitor Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Drug Library | Anti-Cancer Active Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
CAS:363600-92-4
$47.00 / 1mg
-
CAS:944547-46-0
$75.00 / 1mg
-
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
$31.00/1mg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2024-11-19 |
United States